DMK Pharmaceuticals announced that it is reacquiring the rights to its SYMJEPI Injection 0.3mg and SYMJEPI Injection 0.15mg products from USWM. US WorldMeds previously held exclusive distribution and commercialization rights for SYMJEPI and ZIMHI products in the United States, and was responsible for marketing, promotion and distribution efforts. The Company is now actively seeking out-license opportunities for SYMJEPI in the US and globally, in addition to exploring other options with a focus on maximizing value for shareholders.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DMK:
- DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update
- DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023
- DMK Pharmaceuticals reports preclinical results on DPI-125
- DMK Pharmaceuticals announces inducement option grant
Questions or Comments about the article? Write to editor@tipranks.com